TABLE 3.

Degradation Method to Elicit Adalimumab TNF-IR ACR Response

Parameter	ACR20	ACR50	ACR70
Odds ratios (95% CI) for responders
First time TNF inhibitor switcher	0.54 (0.38-0.76)	0.42 (0.27-0.65)	0.28 (0.14-0.55)
Second time TNF inhibitor switcher	0.42 (0.23-0.78)	0.42 (0.20-0.86)	0.50 (0.19-1.32)
Degradation of adalimumab MTX-IR ACR response rates
Adalimumab MTX-IR rate	63.3%	39.1%	20.8%
Degradation process
Odds of response	172.5% (= 63.3% + [100% - 63.3%])	64.2% (= 39.1% + [100% - 39.1%])	26.3% (= 20.8% + [100% - 20.8%])
Adjusted odds	93.1% (= 172.5% x 0.54)	27.0% (= 64.2% x 0.42)	7.4% (= 26.3% x0.28)
Degraded rates (adjusted probabilities)	48.2% (= 93.1% + [100 + 93.1%])	21.2% (= 27.0% + [100 + 27.0%])	6.8% (= 7.4% + [100 + 7.4%])

Source: Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. ³⁵

Note: Odds ratios are presented for ACR response in patients with an inadequate response to a TNF inhibitor compared with TNF inhibitor-naïve patients and the method by which the adalimumab ACR20 response in MTX-IR patients was adjusted to estimate response in TNF-IR patients.

ACR = American College of Rheumatology; CI = confidence interval; MTX-IR = methotrexate inadequate responder; TNF-IR = tumor necrosis factor inhibitor inadequate responder.